NCT06335498View on ClinicalTrials.gov

Further Study of AFGen1 Clinical Performance

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

April 12, 2024

Study Completion Date

April 19, 2024

Conditions
Atrial FibrillationAfibECG
Interventions
DEVICE

ECG co-measurement

Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG

DEVICE

Periodic ECG triggered measurement

Subject triggers AFGen1 to perform an extended measurement during wear period

Trial Locations (1)

98335

1808 49Th St Ct NW, Gig Harbor

All Listed Sponsors
lead

TriVirum, Inc.

INDUSTRY

NCT06335498 - Further Study of AFGen1 Clinical Performance | Biotech Hunter | Biotech Hunter